Instil Bio, Inc.

TIL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item Aug 2026 Jun 2026 May 2026 Mar 2026 Mar 2026 Dec 2025 Nov 2025 Sep 2025
Revenue $2.2M $2.2M $2.2M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $5.1M $5.3M $5.9M
Operating Income $-5.6M $-7.0M $-15.0M
Operating Margin -248.9% -312.7% -670.0%
Interest Expense
Pretax Income
Income Tax Expense
Net Income $-4.3M $-4.2M $-13.6M
Net Margin -191.7% -187.5% -606.0%
EPS (Basic) $-0.63 $-0.62 $-2.01
EPS (Diluted) $-0.63 $-0.62 $-2.01
Shares Outstanding (Basic) 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M
Shares Outstanding (Diluted) 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M 6.8M
Dividends Per Share
← Newer Page 1 of 6 Older →